Pharmacy-based research: reaching consumers where they actually buy
For non-Rx consumer health and nutrition, the community pharmacy is not a fallback site. It is frequently the only setting where the intended user can be reached under real conditions of use.
Insight · · 3 min
Consumer-health and nutrition sponsors face a recruitment paradox that prescription sponsors do not. The people who use their products are everywhere, and traditional hospital research sites reach almost none of them. A hospital site recruits from a clinic population defined by diagnosis and referral. A cough remedy, a probiotic, a joint-support supplement or a self-care analgesic is used by people who never enter that pathway, and who would not describe themselves as patients at all.
The community pharmacy is where those people already are. They buy there, they ask questions there, and increasingly they receive clinical services there. That makes the pharmacy not a second-best substitute for a hospital site but, for a large class of products, the correct research setting, because it is the setting where the product is actually used.
Two developments make this more practical than it was a decade ago. Pharmacy scope of practice has widened substantially across Europe and the UK, with pharmacists routinely delivering vaccination, screening and minor-illness consultations; England's Pharmacy First service, launched in January 2024, is the most visible recent example of a broader trend. And the digital infrastructure that decentralised research built during and after 2020, eConsent, ePRO, remote monitoring, Direct-to-Participant logistics, transfers cleanly into a pharmacy setting. The pharmacist becomes a trained point of contact, not the entire data-capture apparatus.
What a credible pharmacy study requires is more than access to counters, and this is where most attempts fail. Four things have to be built.
Trained pharmacist-investigators. Delegation of study procedures has to be documented, GCP training has to be current where the design requires it, and the pharmacist's role has to be defined precisely enough that an inspector can see where their responsibility begins and ends. A pharmacy is not a site because a study runs in it; it is a site because it has been qualified as one.
Screening that protects data quality. Self-selection at a retail counter is a real threat to validity. Studies in this setting need a second-stage screening step, ideally remote and instrumented, that confirms eligibility independently of the point of recruitment. Without it, the sample is a convenience sample with a pharmacy logo on it.
Capture that does not depend on the counter. eConsent and eDiary should run on the participant's own device after the initial contact, with the pharmacy as the entry point rather than the collection point. This keeps the burden on the pharmacy manageable, which is the single biggest determinant of whether pharmacies stay engaged past the first month, and it produces a cleaner audit trail than paper collected between customers.
A governance model built for the setting. Ethics committees are accustomed to hospital protocols and will ask how oversight works when the investigator is behind a retail counter. That question deserves a proper answer in the submission rather than a paragraph borrowed from a site-based protocol: who supervises, how adverse events are escalated, how source data is retained, how monitoring is performed, and what happens if the pharmacy withdraws.
The scientific argument for the setting is stronger than the logistical one. Consumer-health and nutrition claims are made about products used without supervision, in ordinary conditions, alongside ordinary diets and ordinary adherence. Evidence generated under close clinical supervision, on a population selected for its willingness to attend a hospital, describes a different situation from the one the claim addresses. A study run where the product is bought and used measures the thing the claim is about. That is not a compromise on rigour; it is a better match between the evidence and the assertion it supports.
There is a jurisdictional caveat, and it is the usual one. Whether pharmacy-based research counts as interventional, whether the pharmacist may act as investigator, and what ethics or authority submission is required all vary by country, sometimes substantially between neighbouring member states. A programme designed to the lightest national interpretation will stall at the first border where it does not hold. That mapping belongs at the design stage, not after the first pharmacy has been contracted.
Written by the Evidilya scientific team. For interviews, references or a full publication list, use the contact page.
Talk to our team.
Bring us the evidence question you're wrestling with, we'll tell you the shortest defensible path.